MEDICAL TREATMENT IN PULMONARY HYPERTENSION

Basit Öğe Kaydı
dc.contributor.authorMirici, Arzu
dc.contributor.authorGonlugur, Ugur
dc.date.accessioned2025-01-27T20:43:40Z
dc.date.available2025-01-27T20:43:40Z
dc.date.issued2011
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractSignificant advances in the treatment of pulmonary arterial hypertension have occurred in the last decade. Over this same period, the classification of pulmonary hypertension has also been revised. The most important drugs in the therapy are calcium-channel antagonists, prostanoids, endothelin antagonists, and phosphodiesterase 5 inhibitors. The therapeutic option changes according to the New York Heart Association classification in such patients. The aim of this review is to describe the current state for the treatment of the patients with pulmonary arterial hypertension.
dc.identifier.endpage11
dc.identifier.issn1305-2381
dc.identifier.issue1
dc.identifier.startpage5
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24320
dc.identifier.volume7
dc.identifier.wosWOS:000290003500002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isotr
dc.publisherNobel Ilac
dc.relation.ispartofNobel Medicus
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectPulmonary hypertension
dc.subjecttherapy
dc.subjectbosentan
dc.subjectsildenafil
dc.subjectiloprost
dc.titleMEDICAL TREATMENT IN PULMONARY HYPERTENSION
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu